News

Istaroxime was identified, patented and developed up to phase I by Italian pharmaceutical company Sigma-Tau. Under the terms of the agreement, Debiopharm has the right to develop and

The compound won the designation for the prevention and/or treatment of delayed graft function (DGF) after solid organ transplantation and the treatment of capillary leakage syndrome (CLS). Delayed

This trial is being sponsored by the National Cancer Institute (NCI) under a clinical trials agreement with CuraGen for PXD101, a small molecule histone deacetylase (HDAC) inhibitor. The

The findings from the study, part of a larger, double-blind, placebo-controlled, randomized trial conducted over 14 weeks, specifically showed that liraglutide increased the maximum capacity of beta cells

The patients being enrolled in the trial have chronic, accelerated and blast-phase chronic myeloid leukemia (CML) and have the T315I bcr-abl point mutation, which is associated with resistance

Under the terms of the agreement, Cambrex will manufacture and market products to the research community under the co-exclusive license from Cytori. In return for the license, Cytori

These new findings from phase III studies were presented at the American Diabetes Association (ADA) meeting in Washington, DC. The combination of Galvus, a member of the DPP-4

“Existing intranasal steroids are effective against the nasal symptoms of allergic rhinitis. However, the relief of ocular symptoms remains a key unmet need for patients,” said clinical trial

The addition of these new drugs swells Aida’s product pipeline from four to seven developmental drugs. The three drugs are either being evaluated for pre-clinical trials or in